

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT4577674

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	RELEASE OF SECURITY INTEREST
CONVEYING PARTY DATA	
Name	Execution Date
CYPRESS BIOSCIENCE INC.	08/29/2017
RECEIVING PARTY DATA	
Name:	EXAGEN DIAGNOSTICS, INC.
Street Address:	1261 LIBERTY WAY
Internal Address:	SUITE C
City:	VISTA
State/Country:	CALIFORNIA
Postal Code:	92081
PROPERTY NUMBERS Total: 11	
Property Type	Number
Patent Number:	7582282
Patent Number:	7695908
Patent Number:	6921667
Patent Number:	7563590
Patent Number:	7361517
Patent Number:	7585640
Patent Number:	8080382
Patent Number:	7588905
Patent Number:	8126654
Patent Number:	7390631
Patent Number:	8999921
CORRESPONDENCE DATA	
Fax Number:	(312)913-0002
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	312 913 0001
Email:	allen@mbhb.com
Correspondent Name:	MCDONNELL BOEHNEN HULBERT & BERGHOFF LLP
Address Line 1:	300 SOUTH WACKER DRIVE, SUITE 3100
Address Line 4:	CHICAGO, ILLINOIS 60606

PATENT

NAME OF SUBMITTER:	DAVID HARPER
SIGNATURE:	/David Harper/
DATE SIGNED:	09/01/2017
Total Attachments: 26 source=ConfirmationofTerminationofPatents_asfiled#page1.tif source=ConfirmationofTerminationofPatents_asfiled#page2.tif source=ConfirmationofTerminationofPatents_asfiled#page3.tif source=ConfirmationofTerminationofPatents_asfiled#page4.tif source=ConfirmationofTerminationofPatents_asfiled#page5.tif source=ConfirmationofTerminationofPatents_asfiled#page6.tif source=ConfirmationofTerminationofPatents_asfiled#page7.tif source=ConfirmationofTerminationofPatents_asfiled#page8.tif source=ConfirmationofTerminationofPatents_asfiled#page9.tif source=ConfirmationofTerminationofPatents_asfiled#page10.tif source=ConfirmationofTerminationofPatents_asfiled#page11.tif source=ConfirmationofTerminationofPatents_asfiled#page12.tif source=ConfirmationofTerminationofPatents_asfiled#page13.tif source=ConfirmationofTerminationofPatents_asfiled#page14.tif source=ConfirmationofTerminationofPatents_asfiled#page15.tif source=ConfirmationofTerminationofPatents_asfiled#page16.tif source=ConfirmationofTerminationofPatents_asfiled#page17.tif source=ConfirmationofTerminationofPatents_asfiled#page18.tif source=ConfirmationofTerminationofPatents_asfiled#page19.tif source=ConfirmationofTerminationofPatents_asfiled#page20.tif source=ConfirmationofTerminationofPatents_asfiled#page21.tif source=ConfirmationofTerminationofPatents_asfiled#page22.tif source=ConfirmationofTerminationofPatents_asfiled#page23.tif source=ConfirmationofTerminationofPatents_asfiled#page24.tif source=ConfirmationofTerminationofPatents_asfiled#page25.tif source=ConfirmationofTerminationofPatents_asfiled#page26.tif	

TERMINATION OF SECURITY INTEREST IN TRADEMARKS AND PATENTS

WHEREAS Exagen Diagnostics, Inc., a Delaware corporation with a principal office at 1261 Liberty Way, Suite C, Vista, CA 92081 (the "**Grantor**"), is the owner or licensee of record of the trademarks and applications, now issued or pending in the United States Patent and Trademark Office; and is the owner of record of the patents and patent applications **B**, now issued or pending in the United States Patent and Trademark Office (collectively the "IP"), listed in Exhibit A; and

WHEREAS, the Grantor entered into that certain Security Agreement dated as of October 12, 2010 (the "**Security Agreement**"), between the Grantor and Royalty Pharma Collection Trust ("**Secured Party**"), as successor to Cypress Bioscience Inc. ("**Cypress**"), formerly having a place of business at 4350 Executive Drive, Suite 325, San Diego, California 92121, a true and correct copy of which was recorded by the United States Patent and Trademark Office on June 2, 2010, at Reel 025126, Frame 0245;

WHEREAS, the Secured Party's assets were acquired by the Grantor on October 8, 2010;

WHEREAS, in 2011 Cypress was dissolved and the Secured Party succeeded to all of the Cypress's assets;

WHEREAS Grantor represents that the Note that was secured by the IP, as well the other conditions to release of the security interest in Amendment Number 4 to the Asset Purchase Agreement between Grantor and the Secured Party, executed on October 8, 2013, have been satisfied;

WHEREAS, the Secured Party desires to release its security interest in the IP and terminate the Security Agreement;

NOW, THEREFORE, for good and valuable consideration, receipt of which is hereby acknowledged, Secured Party hereby:

1. releases and reassigns to the Grantor any and all liens, security interests, right, title and interest of Secured Party pursuant to the Security Agreement in the IP more fully described on Exhibit A, without recourse or representation or warranty, express or implied; and
2. authorizes and requests the Commissioner of Patents and Trademarks of the United States of America to note and record the existence of the release hereby given.


IN WITNESS WHEREOF, Secured Party has caused this Termination of Security Interest in Trademarks and Patents to be signed by its duly authorized representative as of this 29th day of August 2017.

Secured Party:

Royalty Pharma Collection Trust,

As successor to Cypress Bioscience Inc.

By: RP Management, LLC,
As Administrator of
Royalty Pharma Collection Trust

By: 

Name: George W. Lloyd

Title: EVP & General Counsel

SCHEDULE A

Cooley Attorney Docket No.	Title	Appln. No.	Filing Date	Patent No./Publication No.	Issue Date/Publication Date	Status
CYPR-044/00US	MARKERS ASSOCIATED WITH METHOTREXATE THERAPY	61/074,532	Jun-20-2008			EXPIRED
CYPR-044/01US	MARKERS ASSOCIATED WITH METHOTREXATE THERAPY	61/218,796	Jun-19-2009			EXPIRED
CYPR-044/02US	MARKERS ASSOCIATED WITH METHOTREXATE THERAPY	61/356,770	Jun-21-2010			PENDING
CYPR-035/00US	METHODS FOR QUANTIFYING METHOTREXATE POLYGLUTAMATES USING TANDEM MASS SPECTROMETRY	61/058,849	Jun-04-2008			EXPIRED
CYPR-027/00US	PREDICTION OF AN INDIVIDUAL'S RISK OF DEVELOPING RHEUMATOID ARTHRITIS	61/047,094	Apr-22-2008			EXPIRED
CYPR-027/01US	PREDICTION OF AN INDIVIDUAL'S RISK OF DEVELOPING RHEUMATOID ARTHRITIS	12/428,299	Apr-22-2009	20090265116	Oct-22-2009	PENDING
CYPR-027/01WO	PREDICTION OF AN INDIVIDUAL'S RISK OF DEVELOPING RHEUMATOID ARTHRITIS	PCT/US2009/ 041443	Apr-22-2009			NATIONAL PHASE DUE 10/22/2010
CYPR-047/00US CELLATOPE	IMPROVEMENTS IN METHODS FOR CALIBRATION OF DIAGNOSTIC INSTRUMENTATION	60/995,712	Sep-27-2007			EXPIRED

Couley Attorney Docket No.	Title	Appln. No.	Filing Date	Patent No./Publication No.	Issue Date/Publication Date	Status
CYPR-047/01US CELLATOPE	IMPROVED BUFFER COMPOSITIONS FOR DIAGNOSTIC ASSAYS	60,995,714	Sep-27-2007			EXPIRED
CYPR-047/01US CELLATOPE	COMPOSITIONS FOR USE AS DIAGNOSTIC ASSAY CONTROLS AND METHODS FOR PRODUCING SAME	60,995,716	Sep-27-2007			EXPIRED
CYPR-047/03US	METHODS AND COMPOSITIONS FOR IMPROVED DIAGNOSTIC ASSAYS	12,743,060	Mar-26-2010			PENDING
CYPR-051/00US	PREDISPOSING GENOTYPE COMBINATIONS IN FOLATE AND ADENOSINE BIOSYNTHESIS	61,174,682	May-01-2009			EXPIRED
CYPR-051/01US	METHODS FOR EVALUATING METHOTREXATE EFFICACY AND/OR TOXICITY	61,316,703	Mar-23-2010			PENDING

Cosley Attorney Docket No.	Title	Appln. No.	Filing Date	Patent No./Publication No.	Issue Date/Publication Date	Status
CYPR-052/00US	CELL-BASED COMPLEMENT ACTIVATION PRODUCT ALGORITHM FOR DIAGNOSING SYSTEMIC LUPUS ERYTHEMATOSUS	61/252,626	Oct-16-2009			PENDING
BISPHOSPHONA TE CYPR-038/01US	COMPOSITIONS COMPRISING A BISPHOSPHONATE AND AN ANTIFOLATE	11/670,674	Feb-02-2007	20070225238	Sep-27-2007	PENDING
SAM-E CYPR-043/00US CYPR-047/01WO	METHODS OF REDUCING MTX TOXICITY	61/136,081	Aug-11-2008			Non-Final Rejection mailed May-25-2010; response due Aug-25- 2010 EXPIRED
	METHODS AND COMPOSITIONS FOR IMPROVED DIAGNOSTIC ASSAYS	PCT/US2008/ 076302	Sep-12-2008			CLOSED

Grantor has co-ownership rights under the following patents and the security interest granted pursuant to this IP Agreement extends only to Grantor's ownership interest in such patents:

CYPR-048/08US CELLATOPE	METHOD FOR DIAGNOSIS AND MONITORING OF DISEASE ACTIVITY AND RESPONSE TO TREATMENT IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) AND OTHER AUTOIMMUNE DISEASES	61/105,863	Oct-16-2008		EXPIRED
CYPR-042/01US CELLATOPE	METHOD FOR DIAGNOSIS AND MONITORING OF DISEASE ACTIVITY AND RESPONSE TO TREATMENT IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) AND OTHER AUTOIMMUNE DISEASES	12/581,057	Oct-16-2009		PENDING
CYPR- 042/01WO	METHOD FOR DIAGNOSIS AND MONITORING OF DISEASE ACTIVITY AND RESPONSE TO TREATMENT IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) AND OTHER AUTOIMMUNE DISEASES	PCT/US200 9/061085	Oct-16-2009		NATIONAL PHASE DUE 4/16/2011

SCHEDULE C

Attorney Docket No.	Title	Appl. No.	Filing Date	Patent No./Publication No.	Issue Date/Publication Date	Status
Klarquist 8123-83095-01-US	DIAGNOSING AND MONITORING INFLAMMATORY DISEASES BY MEASURING	60/570,466	5/11/2004			Expired
Klarquist 8123-83095-02-PCT	DIAGNOSING AND MONITORING INFLAMMATORY DISEASES BY MEASURING	PCT/US2005/016436	5/11/2005			National Filings in AU, CA, EP, JP
Klarquist 8123-83095-03-AU	DIAGNOSING AND MONITORING INFLAMMATORY DISEASES BY MEASURING	2005242719	5/11/2005			Pending
Klarquist 8123-83095-04-CA	DIAGNOSING AND MONITORING INFLAMMATORY DISEASES BY MEASURING	2,564,492	5/11/2005			Pending
Klarquist 8123-83095-05-EP	DIAGNOSING AND MONITORING INFLAMMATORY DISEASES BY MEASURING	5747943.3	5/11/2005			Pending
Klarquist 8123-83095-06-JP	DIAGNOSING AND MONITORING INFLAMMATORY DISEASES BY MEASURING	2007-513201	5/11/2005			Pending
Klarquist 8123-83095-07-US	DIAGNOSING AND MONITORING INFLAMMATORY DISEASES BY MEASURING	10,545,052	10/10/2006	7,585,640	9/8/2009	Issued
Klarquist 8123-83095-08-US	DIAGNOSING AND MONITORING INFLAMMATORY DISEASES BY MEASURING	11/127,348	5/11/2005			Pending
Klarquist 8123-83095-09-US	DIAGNOSING AND MONITORING INFLAMMATORY DISEASES BY MEASURING	12/511,956	7/29/2009			Pending
Klarquist 8123-83095-11-EPC	DIAGNOSING AND MONITORING INFLAMMATORY DISEASES BY MEASURING	10005252.3	5/11/2005			REGISTERED Validated in Belgium, Denmark, Finland, France, Germany, Italy, Luxembourg, the Netherlands, Spain, Sweden, Switzerland, United Kingdom VALIDATED
Klarquist 8123-83095-12-BE	DIAGNOSING AND MONITORING INFLAMMATORY DISEASES BY MEASURING					
Klarquist 8123-	DIAGNOSING AND MONITORING					VALIDATED

83096-05-CN	SYSTEMIC LUPUS (CHINA)	2757691.7	9/9/2002			Pending
Klarquist 8123-83096-06-EP	DIAGNOSIS & MONITORING OF SYSTEMIC LUPUS (EUROPE)					
Klarquist 8123-83096-07-IN	DIAGNOSIS & MONITORING OF SYSTEMIC LUPUS (INDIA)	722/CHENP/2004	9/9/2002			To be Abandoned
Klarquist 8123-83096-08-JP	DIAGNOSIS & MONITORING OF SYSTEMIC LUPUS (JAPAN)	2003-526353	9/9/2002			Pending
Klarquist 8123-83096-09-US	DIAGNOSIS & MONITORING OF SYSTEMIC LUPUS (U.S. NATIONAL STAGE)	10/489,319	3/10/2004	7,390,631	6/24/2008	Issued
Klarquist 8123-83096-10-AU	DIAGNOSIS & MONITORING OF SYSTEMIC LUPUS (AUSTRALIAN DIVISIONAL)	2008202941	7/3/2008			Pending
Klarquist 8123-83096-11-JP	DIAGNOSIS & MONITORING OF SYSTEMIC LUPUS (JAPAN DIVISIONAL)	2009-197692	9/9/2002			Pending
Klarquist 8123-83096-12-BE	DIAGNOSIS & MONITORING OF SYSTEMIC LUPUS (BELGIUM)					VALIDATED
Klarquist 8123-83096-13-DK	DIAGNOSIS & MONITORING OF SYSTEMIC LUPUS (DENMARK)					VALIDATED
Klarquist 8123-83096-14-FI	DIAGNOSIS & MONITORING OF SYSTEMIC LUPUS (FINLAND)					VALIDATED
Klarquist 8123-83096-15-FR	DIAGNOSIS & MONITORING OF SYSTEMIC LUPUS (FRANCE)					VALIDATED
Klarquist 8123-83096-16-DE	DIAGNOSIS & MONITORING OF SYSTEMIC LUPUS (GERMANY)					VALIDATED
Klarquist 8123-83096-17-IT	DIAGNOSIS & MONITORING OF SYSTEMIC LUPUS (ITALY)					VALIDATED
Klarquist 8123-83096-18-LU	DIAGNOSIS & MONITORING OF SYSTEMIC LUPUS (LUXEMBOURG)					VALIDATED
Klarquist 8123-83096-19-NL	DIAGNOSIS & MONITORING OF SYSTEMIC LUPUS (THE NETHERLANDS)					VALIDATED
Klarquist 8123-83096-20-NO	DIAGNOSIS & MONITORING OF SYSTEMIC LUPUS (NORWAY)					VALIDATED
Klarquist 8123-83096-21-ES	DIAGNOSIS & MONITORING OF SYSTEMIC LUPUS (SPAIN)					VALIDATED
Klarquist 8123-83096-22-SE	DIAGNOSIS & MONITORING OF SYSTEMIC LUPUS (SWEDEN)					VALIDATED
Klarquist 8123-83096-23-CH	DIAGNOSIS & MONITORING OF SYSTEMIC LUPUS (SWITZERLAND)					VALIDATED
Klarquist 8123-	DIAGNOSIS & MONITORING OF					VALIDATED

83096-24-GB	SYSTEMIC LUPUS (UNITED KINGDOM)								
Klarquist 8123-83097-01-US	DIAGNOSIS AND MONITORING OF SYSTEMIC LUPUS ERYTHEMATOSUS	60/463,447	4/16/2003					Expired	
Klarquist 8123-83097-02-PCT	IDENTIFICATION AND MONITORING OF SYSTEMIC LUPUS ERYTHEMATOSUS (PCT)	PCT/US2004/011982	4/16/2004					Completed	
Klarquist 8123-83097-03-AU	IDENTIFICATION AND MONITORING OF SYSTEMIC LUPUS ERYTHEMATOSUS	2004232007	4/16/2004					Pending	
Klarquist 8123-83097-04-CA	IDENTIFICATION AND MONITORING OF SYSTEMIC LUPUS ERYTHEMATOSUS	2,522,261	4/16/2004					Pending	
Klarquist 8123-83097-05-EPC	IDENTIFICATION AND MONITORING OF SYSTEMIC LUPUS ERYTHEMATOSUS (EPC)	4759986.5	4/16/2004					Pending	
Klarquist 8123-83097-06-JP	IDENTIFICATION AND MONITORING OF SYSTEMIC LUPUS ERYTHEMATOSUS (JAPAN)	2006-513114	4/16/2004					Pending	
Klarquist 8123-83097-07-US	IDENTIFICATION AND MONITORING OF SYSTEMIC LUPUS ERYTHEMATOSUS	10,552,177	11/20/2006	7,588,965	9/13/2009			Issued	
Klarquist 8123-83097-08-US	IDENTIFICATION AND MONITORING OF SYSTEMIC LUPUS ERYTHEMATOSUS	12,538,001	8/7/2009					Pending	
Klarquist 8123-83100-01-US	MONITORING IMMUNOLOGIC, HEMATOLOGIC AND INFLAMMATORY DISEASES (US)	60/478,493	6/13/2003					Expired	
Klarquist 8123-83100-02-PCT	MONITORING IMMUNOLOGIC, HEMATOLOGIC AND INFLAMMATORY DISEASES (PCT)	PCT/US2004/018552	6/12/2004					Entered National Phase	
Klarquist 8123-83100-03-AU	MONITORING IMMUNOLOGIC, HEMATOLOGIC AND INFLAMMATORY DISEASES (AUSTRALIA)	2004249155	6/12/2004	2004249155				ISSUED	
Klarquist 8123-83100-04-CA	MONITORING IMMUNOLOGIC, HEMATOLOGIC AND INFLAMMATORY DISEASES (CANADA)	2,529,045	6/12/2004					Pending	
Klarquist 8123-83100-05-EP	MONITORING IMMUNOLOGIC, HEMATOLOGIC AND INFLAMMATORY DISEASES (EUROPE)	4776460	6/12/2004	1635892	4/21/2010			ISSUED	

Klarquist 8123-83100-06-IN	MONITORING IMMUNOLOGIC, HEMATOLOGIC AND INFLAMMATORY DISEASES (INDIA)	132/CHENP/20 06	6/12/2004			Abandoned
Klarquist 8123-83100-07-JS	MONITORING IMMUNOLOGIC, HEMATOLOGIC AND INFLAMMATORY DISEASES (ISRAEL)	172488	6/12/2004			Pending
Klarquist 8123-83100-08-JP	MONITORING IMMUNOLOGIC, HEMATOLOGIC AND INFLAMMATORY DISEASES (JAPAN)	2006-533709	6/12/2004			Pending
Klarquist 8123-83100-09-KR	MONITORING IMMUNOLOGIC, HEMATOLOGIC AND INFLAMMATORY DISEASES (KOREA)	10-2005-7023937	6/12/2004			To Be Abandoned
Klarquist 8123-83100-10-NZ	MONITORING IMMUNOLOGIC, HEMATOLOGIC AND INFLAMMATORY DISEASES (NEW ZEALAND)	544223	6/12/2004			To Be Abandoned
Klarquist 8123-83100-11-NO	MONITORING IMMUNOLOGIC, HEMATOLOGIC AND INFLAMMATORY DISEASES (NORWAY)	20058013	6/12/2004			Pending
Klarquist 8123-83100-12-SA	MONITORING IMMUNOLOGIC, HEMATOLOGIC AND INFLAMMATORY DISEASES (SOUTH AFRICA)	200510325	6/12/2004	2005710325	4/30/2008	ISSUED
Klarquist 8123-83100-13-US	MONITORING IMMUNOLOGIC, HEMATOLOGIC AND INFLAMMATORY DISEASES (U.S.)	10/866,509	6/12/2004		10/29/2004	Pending
Klarquist 8123-83100-15-EPC	MONITORING IMMUNOLOGIC, HEMATOLOGIC AND INFLAMMATORY DISEASES (EPC)	10803328.1	6/12/2004			Pending
Klarquist 8123-83100-16-BE	MONITORING IMMUNOLOGIC, HEMATOLOGIC AND INFLAMMATORY DISEASES (BELGIUM)	4776460	6/12/2004	1635692	4/21/2010	Validated
Klarquist 8123-83100-17-DK	MONITORING IMMUNOLOGIC, HEMATOLOGIC AND INFLAMMATORY DISEASES (DENMARK)	4776460	6/12/2004	1635692	4/21/2010	Validated
Klarquist 8123-83100-18-FI	MONITORING IMMUNOLOGIC, HEMATOLOGIC AND	4776460	6/12/2004	1635692	4/21/2010	Validated

Klarquist 8123-83100-19-FR	INFLAMMATORY DISEASES (FINLAND) MONITORING IMMUNOLOGIC, HEMATOLOGIC AND INFLAMMATORY DISEASES (FRANCE)	4776460	6/12/2004	1635692	4/21/2010	Validated
Klarquist 8123-83100-20-DE	MONITORING IMMUNOLOGIC, HEMATOLOGIC AND INFLAMMATORY DISEASES (GERMANY)	4776460	6/12/2004	602004026724-4-08	4/21/2010	Validated
Klarquist 8123-83100-21-IT	MONITORING IMMUNOLOGIC, HEMATOLOGIC AND INFLAMMATORY DISEASES (ITALY)	4776460	6/12/2004	1635692	4/21/2010	Validated
Klarquist 8123-83100-22-LU	MONITORING IMMUNOLOGIC, HEMATOLOGIC AND INFLAMMATORY DISEASES (LUXEMBOURG)	4776460	6/12/2004	1635692	4/21/2010	Validated
Klarquist 8123-83100-23-NL	MONITORING IMMUNOLOGIC, HEMATOLOGIC AND INFLAMMATORY DISEASES (NETHERLANDS)	4776460	6/12/2004	1635692	4/21/2010	Validated
Klarquist 8123-83100-25-ES	MONITORING IMMUNOLOGIC, HEMATOLOGIC AND INFLAMMATORY DISEASES (SPAIN)	4776460	6/12/2004	1635692	4/21/2010	Validated
Klarquist 8123-83100-26-SE	MONITORING IMMUNOLOGIC, HEMATOLOGIC AND INFLAMMATORY DISEASES (SWEDEN)	4776460	6/12/2004	1635692	4/21/2010	Validated
Klarquist 8123-83100-27-CH	MONITORING IMMUNOLOGIC, HEMATOLOGIC AND INFLAMMATORY DISEASES (SWITZERLAND)	4776460	6/12/2004	1635692	4/21/2010	Validated
Klarquist 8123-83100-28-UK	MONITORING IMMUNOLOGIC, HEMATOLOGIC AND INFLAMMATORY DISEASES (UK)	4776460	6/12/2004	1635692	4/21/2010	Validated
Klarquist 8123-83100-29-JP	MONITORING IMMUNOLOGIC, HEMATOLOGIC AND INFLAMMATORY DISEASES (JAPAN)	2010-90939	6/12/2004			Pending
Klarquist 8123-83100-30-HK	MONITORING IMMUNOLOGIC, HEMATOLOGIC AND INFLAMMATORY DISEASES					Pending

Klarquist 8123-83101-01-US	(HONG KONG) REAL TIME METHOD OF DETECTING ACUTE INFLAMMATORY CONDITIONS	60/360,966	4/9/2004				EXPIRED
Klarquist 8123-83101-02-US	REAL TIME METHOD OF DETECTING ACUTE INFLAMMATORY CONDITIONS	60/579,621	6/14/2004				EXPIRED
Klarquist 8123-83101-03-PCT	REAL TIME METHOD OF DETECTING ACUTE INFLAMMATORY CONDITIONS (PCT)	PCT/US2003/01 1914	4/8/2005				NATIONAL PHASE FILINGS-AU, CA, EP, JP
Klarquist 8123-83101-04-AU	REAL TIME METHOD OF DETECTING ACUTE INFLAMMATORY CONDITIONS (AUSTRALIA)	2005241415	4/8/2005				Pending
Klarquist 8123-83101-05-CA	REAL TIME METHOD OF DETECTING ACUTE INFLAMMATORY CONDITIONS (CANADA)	2,361,684	4/8/2005				Pending
Klarquist 8123-83101-06-EP	REAL TIME METHOD OF DETECTING ACUTE INFLAMMATORY CONDITIONS (EUROPE)	5776689.1	4/8/2005	1756571	8/18/2010		ISSUED
Klarquist 8123-83101-07-JP	REAL TIME METHOD OF DETECTING ACUTE INFLAMMATORY CONDITIONS (JAPAN)	2007-507524	4/8/2005				Pending
Klarquist 8123-83101-08-US	REAL TIME METHOD OF DETECTING ACUTE INFLAMMATORY CONDITIONS (U.S.)	11/101,898	4/8/2005	7,361,517	4/22/2008		ISSUED
Klarquist 8123-83101-09-US	REAL TIME METHOD OF DETECTING ACUTE INFLAMMATORY CONDITIONS (U.S.)	11/845,365	8/27/2007				Abandoned
Klarquist 8123-83101-10-BE	REAL TIME METHOD OF DETECTING ACUTE INFLAMMATORY CONDITIONS (BELGIUM)	5776689.1	4/8/2005	1756571	8/18/2010		Validated
Klarquist 8123-83101-11-DK	REAL TIME METHOD OF DETECTING ACUTE INFLAMMATORY CONDITIONS (DENMARK)	5776689.1	4/8/2005	1756571	8/18/2010		Validated
Klarquist 8123-	REAL TIME METHOD OF	5776689.1	4/8/2005	1756571	8/18/2010		Validated

83101-12-FI	DETECTING ACUTE INFLAMMATORY CONDITIONS (FINLAND)						
Klarquist 8123- 83101-13-FR	REAL TIME METHOD OF DETECTING ACUTE INFLAMMATORY CONDITIONS (FRANCE)	5776689.1	4/8/2005	1756571	8/18/2010	Validated	
Klarquist 8123- 83101-14-DE	REAL TIME METHOD OF DETECTING ACUTE INFLAMMATORY CONDITIONS (GERMANY)	5776689.1	4/8/2005	1756571	8/18/2010	Validated	
Klarquist 8123- 83101-15-IT	REAL TIME METHOD OF DETECTING ACUTE INFLAMMATORY CONDITIONS (ITALY)	5776689.1	4/8/2005	1756571	8/18/2010	Validated	
Klarquist 8123- 83101-16-LU	REAL TIME METHOD OF DETECTING ACUTE INFLAMMATORY CONDITIONS (LUXEMBOURG)	5776689.1	4/8/2005	1756571	8/18/2010	Validated	
Klarquist 8123- 83101-17-NL	REAL TIME METHOD OF DETECTING ACUTE INFLAMMATORY CONDITIONS (NETHERLANDS)	5776689.1	4/8/2005	1756571	8/18/2010	Validated	
Klarquist 8123- 83101-18-ES	REAL TIME METHOD OF DETECTING ACUTE INFLAMMATORY CONDITIONS (SPAIN)	5776689.1	4/8/2005	1756571	8/18/2010	Validated	
Klarquist 8123- 83101-19-SE	REAL TIME METHOD OF DETECTING ACUTE INFLAMMATORY CONDITIONS (SWEDEN)	5776689.1	4/8/2005	1756571	8/18/2010	Validated	
Klarquist 8123- 83101-20-CH	REAL TIME METHOD OF DETECTING ACUTE INFLAMMATORY CONDITIONS (SWITZERLAND)	5776689.1	4/8/2005	1756571	8/18/2010	Validated	
Klarquist 8123- 83101-21-GB	REAL TIME METHOD OF DETECTING ACUTE INFLAMMATORY CONDITIONS (UNITED KINGDOM)	5776689.1	4/8/2005	1756571	8/18/2010	Validated	
Klarquist 8123- 83101-22-EPC	REAL TIME METHOD OF DETECTING ACUTE INFLAMMATORY CONDITIONS (EPC)	10005450.1	4/8/2005			Pending	
Klarquist 8123-	REAL TIME METHOD OF					Pending	

SCHEDULE D

Cooley Docket No.	Title	Inventors	Appln. No.	Filing Date	Patent No.	Issue Date	Status
MARKER III GAMPDI, ITPA, IATC, MTR, MTRD)	GENETIC MARKERS FOR PROGNOSIS OF ANTIFOLATE TREATMENT EFFICACY	Guchelaar, Hendrik Jan; Huizinga, Tom Willem Johannes Academisch Ziekenhuis H.O.D.N. LUMC	11/400,232	Apr-10-2006	7,713,696 20070223810 3	May-11-2010 Oct-11-2007	ISSUED Expires: Apr-29-2027 (Apr-10-2026 + 384 days) 1 st fee due: May-12- 2014 Filed divisional directed to ITPA
CYP2- 036/00US PROPR.013A P6008184US P_239HGU							
MARKER III CYP2- 036/01US	GENETIC MARKERS FOR PROGNOSIS OF ANTIFOLATE TREATMENT EFFICACY	Guchelaar, Hendrik Jan; Huizinga, Tom Willem Johannes Academisch Ziekenhuis H.O.D.N. LUMC	12/184,184	Jul-31-2008	2009002937 9	Jan-29-2009	PENDING Jul-12-2010 Requirement for Restriction/Election mailed, response due Aug-12-2010 \$3K
MARKER III CYP2- 036/02US	GENETIC MARKERS FOR PROGNOSIS OF ANTIFOLATE TREATMENT EFFICACY	Guchelaar, Hendrik Jan; Huizinga, Tom Willem Johannes Academisch Ziekenhuis H.O.D.N. LUMC	12/748,838	Mar-29- 2010			PENDING Awaiting examination
MARKER III P6008184EP	GENETIC MARKERS FOR PROGNOSIS OF ANTIFOLATE TREATMENT EFFICACY	Not Available Leids Universitair Medisch Centrum	EP application unavailable				ABANDONED
CYP2-040 Family							
MARKER IV [MTHFD1 (or optionally one of AMPD1,	Pharmacogenetic method for prediction of the efficacy of methotrexate monotherapy in recent-onset arthritis	Hendrik Guchelaar, Gouda, et al. Academisch	60/840,973	Aug-30- 2006			EXPIRED Converted to Utility application

CYPR- 03/01US PROPR.016A	ARTHRITIS	Maria ACADEMISCH ZIEKENHUIS LEIDEN H.O.D.N. LUMC	PCT/NL20 07050146	Apr-08-2007	2007/117141 A1	Oct-18-2007	days) 1st fee due: Apr-21- 2014
RA PREDICTION/ ALGORITHM CYPR- 03/01WO	SYSTEMS AND METHODS FOR PREDICTING AN INDIVIDUAL'S RISK OF DEVELOPING RHEUMATOID ARTHRITIS	Huizinga, Tom Willem Johannes; Van Der Helm-Van Mijl, Anna Helena Maria Academisch Ziekenhuis H.O.D.N. LUMC				CLOSED/PCT PERIOD OVER National Phase deadline 2008-10-07 Instruction sent to LUMC to enter national phase in Europe Canada Australia Japan	
RA PREDICTION/ ALGORITHM P602818SEP P_038THU	SYSTEMS AND METHODS FOR PREDICTING AN INDIVIDUAL'S RISK OF DEVELOPING RHEUMATOID ARTHRITIS	Inventors unavailable Academisch Ziekenhuis Leiden	06112577.4	Apr-07-2006			ABANDONED

SCHEDULE E

Caulley Docket No.	Title	Inventors	Appln. No.	Filing Date	Patent No.	Issue Date	Status
Orgentec (anti-MCV)	METHOD FOR DIAGNOSTICATING RHEUMATIC DISEASES	Bang, Holger Berg, Wigbert Orgentec Diagnostika GmbH	PCT/EP2006/006205	Jun-27-2006	2007/060320 A2 2007/060320 A3	Apr-01-2007 Jul-05-2007	CLOSED Entered national stage in: AU 2006263942 CA 2614103 EP 06762214 US (filing receipt to be confirmed) Mexico (To be confirmed)
Orgentec	METHOD FOR DIAGNOSTICATING RHEUMATIC DISEASES	Bang, Holger Berg, Wigbert Orgentec Diagnostika GmbH	10 2005 029 845.1 2005-06-27	Jan-27-2005	102005029845 A1	Jan-11-2007	PENDING Undergoing preliminary examination Annuity due 2009-06-30 (to be confirmed with Orgentec)
Orgentec	METHOD FOR DIAGNOSTICATING RHEUMATIC DISEASES	Bang, Holger Berg, Wigbert Orgentec Diagnostika GmbH	06762214.2 2006-06-27	Jun-27-2006			PENDING Awaiting examination Annuity due 2009-06-27

SCHEDULE F

Coleley Docket No.	Title	Inventors	Appln. No.	Filing Date	Patent No.	Issue Date	Status
MARKER 1 CYPR-028-03US	METHODS FOR OPTIMIZING CLINICAL RESPONSIVENESS TO METHOTREXATE THERAPY USING METABOLITE PROFILING AND PHARMACOGENETICS	Dervieux, Thierry Walsh, Michael Promethheus Laboratories, Inc.	12/191,287	Aug-13-2008	20090197267	Aug-06-2009	PENDING Awaiting examination
MARKER 1 CYPR-028-02US	METHODS FOR OPTIMIZING CLINICAL RESPONSIVENESS TO METHOTREXATE THERAPY USING METABOLITE PROFILING AND PHARMACOGENETICS	Dervieux, Thierry Walsh, Michael Promethheus Laboratories, Inc.	10/927,904	Aug-26-2004	7,583,282 20050112627	Sep-01-2009 May-26-2005	ISSUED Request for Determination of PTA filed Nov-02-2009 Expires: 2026-03-14 (2024-08-26 + 365 days) 1 st fee due Sep-03-2013 Divisionals filed (RSC-I, ATIC, and TS)
MARKER 1 CYPR-028-03US	METHODS FOR OPTIMIZING CLINICAL RESPONSIVENESS TO METHOTREXATE THERAPY USING METABOLITE PROFILING AND PHARMACOGENETICS	Dervieux, Thierry Walsh, Michael Promethheus Laboratories, Inc.	12/191,286	Oct-29-2008	20090197266	Aug-06-2009	PENDING Awaiting examination
MARKER 1 CYPR-028-02WO	METHODS FOR OPTIMIZING CLINICAL RESPONSIVENESS TO METHOTREXATE THERAPY USING METABOLITE PROFILING AND PHARMACOGENETICS	Dervieux, Thierry Walsh, Michael Promethheus Laboratories, Inc.	PCT/US2004/27851	Aug-27-2004			EXPIRED Entered national stages: EP 04782348.9 CA 2539953
MARKER 1 CYPR-028-02CA	METHODS FOR OPTIMIZING CLINICAL RESPONSIVENESS TO METHOTREXATE THERAPY USING METABOLITE PROFILING AND PHARMACOGENETICS	Dervieux, Thierry Walsh, Michael Promethheus Laboratories, Inc.	2539953	Aug-27-2004			EXAM REQUESTED
MARKER 1	METHODS FOR OPTIMIZING	Dervieux, Thierry	04782348.9	Aug-27-2004			PENDING

CYPR-028/02EP	CLINICAL RESPONSIVENESS TO METHOTREXATE THERAPY USING METABOLITE PROFILING AND PHARMACO-GENETICS	Walsh, Michael Prometheus Laboratories, Inc.					OFFICE ACTION RESPONSE FILED 7/29/2009 DIVISIONAL DUE 2/7/2011
MARKER II (efficacy: MTHFR, SHMT1, toxicity: ATIC, TSER, and MS)	METHODS FOR EVALUATING RISK ASSOCIATED WITH METHOTREXATE THERAPY USING PHARMACOGENETICS	Dervieux, Thierry Smith, Katie M. Prometheus Laboratories Inc.	60676,442	Apr-28-2005			EXPIRED Converted to Utility application
CYPR-034/00US							
MARKER II	METHODS FOR MONITORING METHOTREXATE THERAPY USING PHARMACOGENOMIC AND METABOLITE MARKERS	Dervieux, Thierry Prometheus Laboratories Inc.	60731,598	Oct-27-2005			EXPIRED Converted to Utility application
CYPR-034/01US							
MARKER II	METHODS OF PREDICTING METHOTREXATE EFFICACY AND TOXICITY	Dervieux, Thierry Prometheus Laboratories Inc.	117380,171	Apr-25-2006	2006/0286371	Dec-21-2006	PENDING Response to Non-Final Rejection filed Feb-23-2010 Filed divisional directed to SHMT1 (efficacy) and TSER and MS (toxicity) PENDING Awaiting examination
CYPR-034/03US	METHODS OF PREDICTING METHOTREXATE EFFICACY AND TOXICITY	Dervieux, Thierry Prometheus Laboratories Inc.	12194,503	Aug-19-2008			PENDING Awaiting examination
MARKER II	METHODS OF PREDICTING METHOTREXATE EFFICACY AND TOXICITY	Dervieux, Thierry Prometheus Laboratories Inc.	12194,501	Aug-19-2008			PENDING Awaiting examination
CYPR-034/04US							
MARKER II	METHODS OF PREDICTING METHOTREXATE EFFICACY AND TOXICITY	Dervieux, Thierry Prometheus Laboratories Inc.	PC7US006/ 16346	Apr-26-2006			EXPIRED Entered National Stages: AU 2006239279
CYPR-034/02WO							

25.

MARKER II CYPR-034/02AU	METHODS OF PREDICTING METHOTREXATE EFFICACY AND TOXICITY	Dervieux, Thierry Prometheus Laboratories, Inc.	20060239279	Apr-26-2006			CA 2806424 EP 06751770.6 EXAM REQUESTED
MARKER II CYPR-034/03CA	METHODS OF PREDICTING METHOTREXATE EFFICACY AND TOXICITY	Dervieux, Thierry Prometheus Laboratories, Inc.	2806424	Apr-26-2006			REQUEST FOR EXAM JULIE 4/26/2011
MARKER II CYPR-034/02EP	METHODS OF PREDICTING METHOTREXATE EFFICACY AND TOXICITY	Dervieux, Thierry Prometheus Laboratories, Inc.	06751770.6	Apr-26-2006			EXAM REQUESTED
MARKER V (CD30/CD26) CYPR-033/00US	BIOMARKERS ASSOCIATED WITH RESPONSE TO CHEMOTHERAPY	Marcellini, John F. Dervieux, Thierry Simpson, Lynn A. Prometheus Laboratories, Inc.	10/971,757	Oct-22-2004			ABANDONED Abandoned per JA's email instruction (Oct-14-2009)
MTXPG I (UGH conversion) CYPR-036/00US	METHODS OF QUANTIFYING METHOTREXATE METABOLITES	Dervieux, Thierry; Richerson, Russell B. Prometheus Laboratories, Inc.	10/213,760	Aug-30-2002	7,563,590 20040043441	Jul-21-2009 Mar-04-2004	ISSUED Expires: Jan-23-2023 (Aug-30-2022 + 877) 1st fee due Jul-22-2013
MTXPG I CYPR-030/00WO	METHODS OF QUANTIFYING METHOTREXATE METABOLITES	Dervieux, Thierry Richerson, Russell, B. Prometheus Laboratories, Inc.	PCT/US2003/ 27313	Aug-28-2003			EXPIRED Entered National Stages: AU 2003270046 CA 2496901 EP 03751939.4
MTXPG I CYPR-030/00AU	METHODS OF QUANTIFYING METHOTREXATE METABOLITES	Dervieux, Thierry Richerson, Russell, B. Prometheus Laboratories, Inc.	2003270046	Aug-28-2003	2003270046	9/17/2009	REGISTERED

MTXPG I CYPR-030/00CA	METHODS OF QUANTIFYING METHOTREXATE METABOLITES	Dervieux, Thierry Richerson, Russell, B. Prometheus Laboratories, Inc.	2496901	Aug-28-2003			PENDING OFFICE ACTION RESPONSE FILED 5/27/2010
MTXPG I CYPR-030/00EP	METHODS OF QUANTIFYING METHOTREXATE METABOLITES	Dervieux, Thierry Richerson, Russell, B. Prometheus Laboratories, Inc.	03751939.4	Aug-28-2003			PENDING OFFICE ACTION RESPONSE FILED 10/8/2009 DIVISIONAL DUE 4/2/2011
MTXPG I CYPR-030/01AU	METHODS OF QUANTIFYING METHOTREXATE METABOLITES	Dervieux, Thierry Richerson, Russell, B. Prometheus Laboratories, Inc.	2609212943	Aug-28-2003			Divisional of CYPR- 030/00AU OFFICE ACTION ISSUED RESPONSE DUE 10/19/2010
MTXPG II (MTXPG assay) CYPR-032/00US	METHODS FOR DIRECT DETECTION OF INDIVIDUAL METHOTREXATE METABOLITES	Dervieux, Thierry Richerson, Russell Prometheus Laboratories, Inc.	10/384,066	Mar-07-2003	6,921,667 20040175834	Jul-26-2005 Sep-09-2004	ISSUED Expiration date: May-22- 2023 (Mar-07-2023 + 76 days) 1st fee paid 2nd fee due Jul-26-2013
MTXPG II CYPR-032/00WO	METHODS FOR DIRECT DETECTION OF INDIVIDUAL METHOTREXATE METABOLITES	Dervieux, Thierry Richerson, Russell Prometheus Laboratories, Inc.	PCT/US2004/ 06312	Mar-02-2004			EXPIRED Entered National Stage: AU 2004219711 EP 04716493 JP 2006-308989 CA 2517709
MTXPG II CYPR-032/00AU	METHODS FOR DIRECT DETECTION OF INDIVIDUAL METHOTREXATE METABOLITES	Dervieux, Thierry Richerson, Russell Prometheus	2004219711	Mar-02-2004			ALLOWED AWAITING LETTERS PATENT

MTXPG II CYPR-032/00CA	METHODS FOR DIRECT DETECTION OF INDIVIDUAL METHOTREXATE METABOLITES	Laboratories, Inc. Dervieux, Thierry Richerson, Russell	2517709	Mar-02-2004	1604203	10/28/2009	REGISTERED Validated in Belgium, Denmark, Finland, France, Germany, Italy, Luxembourg, the Netherlands, Spain, Sweden, Switzerland, United Kingdom
MTXPG II CYPR-032/00EP	METHODS FOR DIRECT DETECTION OF INDIVIDUAL METHOTREXATE METABOLITES	Prometheus Laboratories, Inc.	04716493.4	Mar-02-2004	1604203	10/28/2009	REGISTERED
MTXPG II CYPR-032/00BE	METHODS FOR DIRECT DETECTION OF INDIVIDUAL METHOTREXATE METABOLITES	Dervieux, Thierry Richerson, Russell	04716493.4	Mar-02-2004	1604203	10/28/2009	REGISTERED
MTXPG II CYPR-032/00DK	METHODS FOR DIRECT DETECTION OF INDIVIDUAL METHOTREXATE METABOLITES	Prometheus Laboratories, Inc.	04716493.4	Mar-02-2004	1604203	10/28/2009	REGISTERED
MTXPG II CYPR-032/00FI	METHODS FOR DIRECT DETECTION OF INDIVIDUAL METHOTREXATE METABOLITES	Dervieux, Thierry Richerson, Russell	04716493.4	Mar-02-2004	1604203	10/28/2009	REGISTERED
MTXPG II CYPR-032/00FR	METHODS FOR DIRECT DETECTION OF INDIVIDUAL METHOTREXATE METABOLITES	Prometheus Laboratories, Inc.	04716493.4	Mar-02-2004	1604203	10/28/2009	REGISTERED
MTXPG II CYPR-032/00DE	METHODS FOR DIRECT DETECTION OF INDIVIDUAL METHOTREXATE METABOLITES	Dervieux, Thierry Richerson, Russell	04716493.4	Mar-02-2004	1604203	10/28/2009	REGISTERED
MTXPG II CYPR-032/00IT	METHODS FOR DIRECT DETECTION OF INDIVIDUAL METHOTREXATE METABOLITES	Prometheus Laboratories, Inc.	04716493.4	Mar-02-2004	1604203	10/28/2009	REGISTERED

MTXPG II CYPR-032/00LU	METHODS FOR DIRECT DETECTION OF INDIVIDUAL METHOTREXATE METABOLITES	Prometheus Laboratories, Inc. Dervieux, Thierry Richerson, Russell	04716493.4	Mar-02-2004	1604203	10/28/2009	REGISTERED
MTXPG II CYPR-032/00ML	METHODS FOR DIRECT DETECTION OF INDIVIDUAL METHOTREXATE METABOLITES	Prometheus Laboratories, Inc. Dervieux, Thierry Richerson, Russell	04716493.4	Mar-02-2004	1604203	10/28/2009	REGISTERED
MTXPG II CYPR-032/00ES	METHODS FOR DIRECT DETECTION OF INDIVIDUAL METHOTREXATE METABOLITES	Prometheus Laboratories, Inc. Dervieux, Thierry Richerson, Russell	04716493.4	Mar-02-2004	1604203	10/28/2009	REGISTERED
MTXPG II CYPR-032/00SE	METHODS FOR DIRECT DETECTION OF INDIVIDUAL METHOTREXATE METABOLITES	Prometheus Laboratories, Inc. Dervieux, Thierry Richerson, Russell	04716493.4	Mar-02-2004	1604203	10/28/2009	REGISTERED
MTXPG II CYPR-032/00CH	METHODS FOR DIRECT DETECTION OF INDIVIDUAL METHOTREXATE METABOLITES	Prometheus Laboratories, Inc. Dervieux, Thierry Richerson, Russell	04716493.4	Mar-02-2004	1604203	10/28/2009	REGISTERED
MTXPG II CYPR-032/00GB	METHODS FOR DIRECT DETECTION OF INDIVIDUAL METHOTREXATE METABOLITES	Prometheus Laboratories, Inc. Dervieux, Thierry Richerson, Russell	04716493.4	Mar-02-2004	1604203	10/28/2009	REGISTERED
MTXPG II CYPR-032/00HK	METHODS FOR DIRECT DETECTION OF INDIVIDUAL METHOTREXATE METABOLITES	Prometheus Laboratories, Inc. Dervieux, Thierry Richerson, Russell	06102244.4	Mar-02-2004			PUBLISHED
MTXPG II CYPR-032/00JP	METHODS FOR DIRECT DETECTION OF INDIVIDUAL METHOTREXATE METABOLITES	Prometheus Laboratories, Inc. Dervieux, Thierry Richerson, Russell	2006-508389	Mar-02-2004			TAKE NO FURTHER ACTION-TO BE ABANDONED
MTXPG II CYPR-032/01EP	METHODS FOR DIRECT DETECTION OF INDIVIDUAL METHOTREXATE METABOLITES	Prometheus Laboratories, Inc. Dervieux, Thierry Richerson, Russell	09013484.2	Mar-02-2004			Divisional of CYPR- 032/00EP

MTXPG II CYPR-032/01HK	Prometheus Laboratories, Inc. Dervieux, Thierry Richerson, Russell Prometheus Laboratories, Inc.	10103341	Mar-02-2004				PUBLISHED
MTXPG III CYPR-029/01US	Prometheus Laboratories, Inc.	80580,141	Jun-15-2004				EXPIRED
MTXPG III CYPR-029/01US	Prometheus Laboratories, Inc.	11/152,128	Jun-13-2005	7,695,908	Apr-13-2010	Converted To Utility Application	ISSUED
MTXPG III CYPR-029/02US	Prometheus Laboratories, Inc.	12/698,966	Feb-02-2010	20060057609	Mar-16-2006	Expires: Oct-15-2027 (Jun-13-2025 + 854 days)	Expires: Oct-15-2027 (Jun-13-2025 + 854 days)
MTXPG III CYPR-029/01W0	Prometheus Laboratories, Inc.	PC17US2005 720957	Jun-14-2005			1 st fee due: Apr-14-2014	PENDING
MTXPG III CYPR-029/01EP	Prometheus Laboratories, Inc.	2,591,610	Jun-14-2005			Awaiting examination	EXPIRED
						Entered National Stages: AU 2005257949 CA 2,591,610 EP 05762844.2 JP 2007-546642	PENDING
						OFFICE ACTION RESPONSE FILED 11/10/2009	

CYPR-029 Family

MTXPG III CYPR-029/01JP	METHODS FOR PREDICTING METHOTREXATE POLYGLUTAMATE LEVELS USING PHARMACO-GENETICS	Dervieux, Thierry Prometheus Laboratories, Inc.	2007- 316642	Jun-14-2005				ABANDONED
MTXPG III CYPR-029/01CA	METHODS FOR PREDICTING METHOTREXATE POLYGLUTAMATE LEVELS USING PHARMACO-GENETICS	Dervieux, Thierry Prometheus Laboratories, Inc.	2,591,610	Jun-14-2005				EXAM REQUESTED
MTXPG III CYPR-029/01AU	METHODS FOR PREDICTING METHOTREXATE POLYGLUTAMATE LEVELS USING PHARMACO-GENETICS	Dervieux, Thierry Prometheus Laboratories, Inc.	2005257949	Jun-14-2005				OFFICE ACTION ISSUED Response Due 1/20/2011
Compliance Packaging CYPR-031/00US	METHOTREXATE COMPLIANCE PACKAGING	Walsh, Michael J.; Prometheus Laboratories, Inc.	10,384,353	Mar-06-2003	20040176381	Sep-09-2004		ABANDONED
Compliance Packaging CYPR-031/01US	METHOTREXATE COMPLIANCE PACKAGING	Walsh, Michael J.; Prometheus Laboratories, Inc.	11,555,216	Oct-31-2006	20070093497	Apr-26-2007		ABANDONED